Mount Yale Investment Advisors LLC Acquires 162 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mount Yale Investment Advisors LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,563 shares of the medical research company’s stock after acquiring an additional 162 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $634,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS bought a new stake in Edwards Lifesciences in the third quarter worth $40,000. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Piper Sandler cut their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Stock Performance

NYSE EW opened at $72.52 on Wednesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $42.77 billion, a PE ratio of 10.46, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The business’s 50-day moving average price is $72.32 and its 200 day moving average price is $70.19. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,000 shares of company stock valued at $2,195,180. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.